Novartis reports on the discovery of phosphatidylinositol-4 kinase (PfPI4K) as the target of a class of experimental antimalarial drugs called the imidazopyrazines, which has the potential to prevent, block and treat multiple stages of the malaria lifecycle.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Whitehouse Laboratories announces the development of a Container Testing Center to open in 2014.

Catalent opens clinical-trial supply facility in Shanghai, China.

Baxter and Cell Therapeutics enter a licensing agreement to develop and commercialize pacritinib.

Thermo Fisher must divest of cell culture media and sera lines, and other businesses, in purchase of Life Technologies.

Almac releases an enhanced third-party logistics customer billing application.

Harlan Korea appoints Kwan Goo Edmond (Ed) Cho as its new president.

Pure MHC and Catalent sign an agreement to develop RL21A using Catalent's GPEx technology.

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.

Stada licenses 3M's transdermal technology for a fentanyl patch.

Mylan and the Indian biopharmaceutical company Biocon receive approval for a biosimilar version of trastuzumab in India. Also, Mylan and Teva reach settlement on Copaxone in the EU.

European Medicines Agency announces the launch of the Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE) project.

Coldstream Laboratories names director of formulation development.

GlaxoSmithKline plans to invest nearly $41 million to expand its operations at its facility in Montrose, the United Kingdom.

Camargo Pharmaceuticals appoints a veteran health executive as new COO.

Merck KGaA plans to build a new biomanufacturing facility in Nantong, China.

CareFusion will acquire GE Healthcare’s Vital Signs division.

Phase I/II study to evaluate treatment of patients with melanoma using Pfizer's spalbociclib and GSK's trametinib.

Manufacturing of products made at the Barceloneta, Puerto Rico plant will be moved to other sites.

Unilife to begin commercial supply in 2014.

Annual growth in spending for medicines is expected to rise from 2-3% in 2013 to 5-7% in 2017, the highest pace of growth since 2009.

GlaxoSmithKline will build a new solid dosage manufacturing facility in India.

Catalent has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.

Plan outlines key areas of collaboration.

An operational-excellence initiative increased collaboration between operations and quality personnel to address human-error-caused deviations.

New CDMO to be formed from the combination of DSM Pharmaceutical Products and Patheon in a $2.6-billion transaction.